| Autor: |
Kim DJ; Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Chosun University College of Medicine and Medical School, Gwangju, Korea., Cho SY; Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Chosun University College of Medicine and Medical School, Gwangju, Korea., Jung KT; Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Chosun University College of Medicine and Medical School, Gwangju, Korea. |
| Jazyk: |
angličtina |
| Zdroj: |
Korean journal of anesthesiology [Korean J Anesthesiol] 2024 Aug; Vol. 77 (4), pp. 411-422. Date of Electronic Publication: 2023 Aug 21. |
| DOI: |
10.4097/kja.23530 |
| Abstrakt: |
Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that has been used for several decades to reduce blood loss during surgery and after trauma. TXA was traditionally used to reduce bleeding in various clinical settings such as menorrhagia, hemophilia, or other bleeding disorder. Numerous studies have demonstrated the efficacy of TXA in reducing blood loss and the need for transfusions. Interest in the potential applications of TXA beyond its traditional use has been growing recently, with studies investigating the use of TXA in postpartum hemorrhage, cardiac surgery, trauma, neurosurgery, and orthopedic surgery. Despite its widespread use and expanding indications, data regarding the safe and appropriate use of TXA is lacking. Recent clinical trials have found various potential risks and limitations in the long-term benefits of TXA. This narrative review summarizes the clinical applications and limitations of TXA. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
